simvastatin has been researched along with Arteriosclerosis in 114 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (1.75) | 18.7374 |
| 1990's | 36 (31.58) | 18.2507 |
| 2000's | 72 (63.16) | 29.6817 |
| 2010's | 3 (2.63) | 24.3611 |
| 2020's | 1 (0.88) | 2.80 |
| Authors | Studies |
|---|---|
| Buckett, L; Davidson, R; Holdgate, G; McCormick, A; McTaggart, F; Schneck, D; Smith, G; Warwick, M | 1 |
| Bea, AM; Benaiges, D; Blanco-Vaca, F; Brea-Hernando, Á; Climent, E; Pedro-Botet, J; Perea, V; Pintó, X; Plana, N; Suárez-Tembra, M | 1 |
| Chen, JS; Chen, JW; Huang, PH; Lai, CF; Lin, CP; Lin, SJ | 1 |
| Agarwal, S; Desai, M; Gautam, S; Gottlieb, I; Lima, JA; Steen, H; Warren, WP; Xavier, SS | 1 |
| Boffi, L; Capra, A; Corsi, D; Failla, M; Fantini, E; Gentile, G; Giannattasio, C; Maestroni, S; Mancia, G; Meles, E; Scotti, V | 1 |
| Catanozi, S; Chiquito, FC; Nakandakare, ER; Passarelli, M; Quintão, EC; Rocha, JC | 1 |
| Chen, JX; Chen, L; Chen, XC; Cheng, ZH; Tong, XJ; Xiang, XY | 1 |
| Chen, MS; He, ZC; Lu, DF; Wang, W; Wu, J; Xiao, Y | 1 |
| Boyer, O; Brakenhielm, E; Freguin-Bouillant, C; Henry, JP; Lallemand, F; Plissonnier, D; Roux, N; Thuillez, C | 1 |
| Libby, P; Sukhova, GK; Williams, JK | 1 |
| Bea, F; Bennett, B; Blessing, E; Levitz, M; Rosenfeld, ME; Wallace, EP | 1 |
| Badimon, JJ; Corti, R; Fayad, ZA; Fuster, V; Helft, G; Mercuri, M; Mizsei, G; Smith, D; Weinberger, J; Wentzel, J; Worthley, SG | 1 |
| Aparicio, C; Blanco-Colio, LM; Egido, J; Gómez-Gerique, J; Hernández-Presa, MA; Martín-Ventura, JL; Mas, S; Ortega, L; Ortego, M; Tuñón, J; Vivanco, F | 1 |
| Bakker, HD; de Jongh, S; Kastelein, JJ; Lilien, MR; op't Roodt, J; Stroes, ES | 1 |
| Harman, SM; Hecht, HS | 1 |
| Bea, F; Blessing, E; Rosenfeld, ME; Shelley, MI; Shultz, JM | 1 |
| de Boo, T; Kastelein, JJ; Smilde, TJ; Stalenhoef, AF; Trip, MD; van Wissen, S | 1 |
| Burger, F; Graber, P; Kwak, BR; Lüscher, TF; Mach, F; Matter, CM; Mulhaupt, F; Pelli, G; Veillard, NR | 1 |
| Fan, HZ; Huang, ZY; Rui, YC; Yang, PY; Yu, YL | 1 |
| de Groot, E; Hutten, BA; Kastelein, JJ; Smilde, TJ; Stalenhoef, AF; van Wissen, S | 1 |
| Berger, T; Daniel, WG; Garlichs, CD; Ludwig, J; Raaz, D; Reiss, C; Steinkasserer, A; Stumpf, C; Tantawi, O; Weng, A; Yilmaz, A | 1 |
| Badimon, JJ; Chaplin, WF; Corti, R; Fallon, JT; Fuster, V; Jneid, H; Mizsei, G; Osende, JI; Wright, SD | 1 |
| Echizen, H; Hiraga, M; Ida, T; Oishi, K; Uchida, MK; Yamaguchi, T | 1 |
| de Grooth, GJ; Fruchart, JC; Kastelein, JJ; Klerkx, AH; Kuivenhoven, JA; Smilde, TJ; Stalenhoef, AF; Van Wissen, S; Zwinderman, AH | 1 |
| Barter, PJ; Bonnet, J; Cheung, RC; Kallend, D; Morrell, JM; Raza, A; Schuster, H; Stender, S; Watkins, C | 1 |
| Andreassen, AK; Aukrust, P; Gullestad, L; Hognestad, A; Holm, T; Kjekshus, JK; Semb, AG; Stokke, O; Wergeland, R | 1 |
| Bell, PR; Loftus, IM; Molloy, KJ; Naylor, AR; Schwalbe, EC; Thompson, MM | 1 |
| Cesari, M; Pessina, AC | 1 |
| Jacobson, MS; Kohn, M | 1 |
| Hryszko, T; Malyszko, J; Malyszko, JS; Mysliwiec, M | 1 |
| Hayashi, M; Ichihara, A; Kaneshiro, Y; Koura, Y; Saruta, T; Tada, Y | 1 |
| Gao, YH; Zhang, M; Zhang, W; Zhang, Y; Zhang, YY; Zhao, YX | 1 |
| Desai, MY; Gautam, S; Lai, S; Lima, JA; Steen, H; Warren, WP | 1 |
| Gordon, BR; Levine, DM; Parker, TS; Rosenson, RS; Tangney, CC | 1 |
| Adams, GJ; Ballantyne, CM; Greene, J; Harrist, R; Insull, W; Karmonik, C; Kimball, KT; Morrisett, JD; Vick, GW | 1 |
| Wang, YX | 1 |
| Bays, HE; Blasetto, JW; Cain, VA; Deedwania, PC; Hunninghake, DB; Jones, PH | 1 |
| Ito, T; Shiomi, M; Yamada, S | 1 |
| Kopecky, M; Nachtigal, P; Semecky, V; Solichova, D; Zdansky, P | 1 |
| Cui, Y; Liu, H; Ning, Z; Qing, X; Wu, C; Yang, J; Yu, S; Zhao, D | 1 |
| Almeida, EA; Carneiro, A; Jorge, M; Jorge, PA; Ozaki, MR | 1 |
| Badimon, JJ; Chaplin, WF; Corti, R; Fayad, ZA; Fuster, V; Helft, G; Mizsei, G; Muntwyler, J; Smith, DA; Viles-Gonzalez, JF; Weinberger, J; Worthley, SG | 1 |
| Bellasi, A; Raggi, P | 1 |
| Alonso, SS; Biagini, GL; Coelho, JF; Gama, MP; Martins, CF; Pellegrinello, S | 1 |
| Spence, JD | 1 |
| Ho, W; Huo, Y; Liu, ZP; Meng, L | 1 |
| Bernini, F; Corsini, A; Fumagalli, R; Paoletti, R; Raiteri, M; Soma, MR | 1 |
| Dowell, FJ; Hamilton, CA; Lindop, GB; Reid, JL | 1 |
| Amano, M; Ino, T; Kasuga, M; Kazumi, T; Matsuba, K; Ohki, A; Yoshino, G | 1 |
| Billingham, ME; Devens, C; Hammer, C; Meiser, BM; Reichart, B; Seidel, D; Thiery, J; Wenke, K; Wolf, S | 1 |
| Catapano, AL; Corsini, A; Maggi, FM | 1 |
| Brandl, U; Detter, C; Kreuzer, E; Kur, F; Mair, H; Meiser, BM; Seidel, D; Thiery, J; Uberfuhr, P; Wenke, K | 1 |
| Ravnskov, U | 1 |
| Arnaboldi, L; Corsini, A; Fumagalli, R; Paoletti, R; Quarato, P; Raiteri, M | 1 |
| Cooper, ME; Gilbert, RE; Jerums, G | 1 |
| Abe, Y; Ballantyne, CM; Dunn, K; Gotto, AM; Hackman, A; Insull, W; Pownall, H; Smith, L | 1 |
| Clem, JR | 1 |
| Buckley, BM; Murphy, MB; Vaughan, CJ | 1 |
| Dwight, JF; Hendry, BM; Mendes Ribeiro, AC | 1 |
| Faergeman, O; Kjekshus, J; Olsson, AG; Pedersen, TR; Pyŏrälä, K; Thorgeirsson, G | 1 |
| Fager, G; Lennernäs, H | 1 |
| Biwa, T; Hakamata, H; Horiuchi, S; Kobori, S; Matsumura, T; Sakai, M; Sato, Y; Shichiri, M; Takemura, T | 1 |
| Cook, TJ; Haghfelt, T; Kjekshus, J; Musliner, TA; Olsson, AG; Pedersen, TR; Pyörälä, K; Tobert, JA | 1 |
| De Caterina, R; Lenzi, S | 1 |
| La Fata, V; Laufs, U; Liao, JK; Plutzky, J | 1 |
| de Jong, SA; Nye, ER; Restieaux, NJ; Robertson, MC; Sutherland, WH; Walker, HL; Williams, MJ | 1 |
| Pedersen, TR | 1 |
| Wehmeier, T; Ziajka, PE | 1 |
| Bakker-Arkema, RG; Black, DM; Brown, AS; Campbell, CF; Guthrie, R; Henley, RW; Koren, M; McLain, R; Woo, W; Yellen, L | 1 |
| Eriksson, M | 1 |
| Sinzinger, H | 1 |
| Echeandia, C; Figuerola, A; Marta-Moreno, J; Mola, S; Oliveros-Cid, A | 1 |
| Mégnien, JL; Simon, A | 1 |
| Banks, T | 1 |
| Badimon, L; Llorente-Cortés, V; Martínez-González, J | 1 |
| Bartek, J; Růzicka, V; Stejskal, D | 1 |
| Alfon, J; Badimon, L; Berrozpe, M; Guasch, JF | 1 |
| Taskinen, MR | 1 |
| Joffe, BI; Kotze, MJ; Pilcher, GJ; Raal, FJ; Veller, MG | 1 |
| Davignon, J; Laaksonen, R | 1 |
| Stalenhoef, AF; Stehouwer, CD | 1 |
| Bellosta, S; Bernini, F; Corsini, A; Ferri, N; Paoletti, R | 1 |
| Barberi, L; Catapano, AL; Norata, GD; Pirillo, A; Roma, P; Zanelli, T; Zhu, W | 1 |
| Kastelein, JJ; Smilde, TJ; Stalenhoef, AF; van den Berkmortel, FW; van Langen, H; Wollersheim, H | 1 |
| Arnaboldi, L; Bellosta, S; Bernini, F; Corsini, A; Ferri, N; Paoletti, R | 1 |
| Yokode, M | 1 |
| Chehne, F; Kritz, H; Schmid, P; Sinzinger, H | 1 |
| Simons, M | 1 |
| Bandinelli, S; Dell'Omo, G; Mariani, M; Pedrinelli, R; Penno, G | 1 |
| Ose, L; Risberg, K; Svilaas, A; Thoresen, M | 1 |
| Emeis, JJ; Lankelma, J; Nègre-Aminou, P; van Hinsbergh, VW; van Nieuw Amerongen, GP; Vermeer, MA | 1 |
| Burton, CA; Chao, YS; Detmers, PA; Hassing, H; Hermanowski-Vosatka, A; Hernandez, M; Mundt, S; Patel, S; Peterson, L; Rosa, R; Sparrow, CP; Wang, PR; Wright, SD; Zhang, D | 1 |
| Harangi, M; Paragh, G | 1 |
| Bonaiuto, M; Campo, GM; Castaldo, M; Cinquegrani, M; Maesano, A; Saitta, A; Sardo, MA; Schepis, F; Squadrito, F; Zema, MC | 1 |
| Fagan, SC; Hess, DC | 1 |
| Badimon, L; Martínez-González, J; Raposo, B; Rodríguez, C | 1 |
| Hayashi, T; Iguchi, A; Kano, H; Sumi, D; Thakur, NK; Tsunekawa, T | 1 |
| Auerbach, B; Bak Mueller, S; Bocan, TM; Dagle, C; Krause, BR; Lu, X; Rosebury, WS; Sliskovic, DR | 1 |
| Ahn, JY; Choi, IS; Choi, YM; Jin, DK; Koh, KK; Park, GS; Shin, EK; Sohn, MS; Son, JW | 1 |
| Badimon, JJ; Chesebro, J; Corti, R; Fayad, ZA; Fuster, V; Helft, G; Mercuri, M; Worthley, SG | 1 |
| Wierzbicki, AS | 1 |
| Susekov, AV | 1 |
| Meng, CQ | 1 |
| Donovan, KD; Roberts, CS | 1 |
| Steiner, G | 1 |
| Brodsky, S; Goligorsky, MS; Iden, C; Lewis, A; Li, H; Rieger, R | 1 |
| da Cunha, V; Dole, W; Hinchman, J; Huw, LY; Kauser, K; Martin-McNulty, B; Post, J; Sullivan, ME; Vergona, R; Wang, YX | 1 |
| Itakura, H | 1 |
| Bruckert, E; Gagné, C; Gaudet, D | 1 |
| de Góes, JM; Dereviack, BE; Diament, J; Forti, N; Giannini, SD; Machado, C | 1 |
| Bach, LA; Cooper, ME; Jerums, G; O'Brien, RC | 1 |
| Ishida, F; Kamei, T; Kobayashi, M; Ohmura, I; Taguchi, K; Takahashi, T; Watanabe, K | 1 |
| MacDonald, JS; Slater, EE | 1 |
26 review(s) available for simvastatin and Arteriosclerosis
| Article | Year |
|---|---|
[Study of arterial distensibility in man. Modulating mechanisms, pathological conditions and effects of treatment].
Topics: Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Arteries; Arteriosclerosis; Compliance; Diabetes Mellitus; Diuretics; Drug Therapy, Combination; Elasticity; Heart Failure; Humans; Hypercholesterolemia; Hypertension; Risk Factors; Simvastatin; Treatment Outcome | 2003 |
Pitfalls in the assessment of murine atherosclerosis.
Topics: Animals; Anticholesteremic Agents; Aorta; Arteriosclerosis; Cholesterol; Disease Models, Animal; Humans; Mice; Simvastatin; Tunica Intima | 2009 |
Combined antihypertensive and lipid-lowering treatment.
Topics: Anticholesteremic Agents; Antihypertensive Agents; Arteriosclerosis; Cardiovascular Diseases; Comorbidity; Drug Therapy, Combination; Endothelium, Vascular; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Nifedipine; Pyridines; Simvastatin | 2004 |
Cholesterol (and cardiovascular risk) in adolescence.
Topics: Adolescent; Anticholesteremic Agents; Arteriosclerosis; Cholesterol; Humans; Lovastatin; Obesity; Risk Factors; Simvastatin | 2004 |
Cardiovascular functional phenotypes and pharmacological responses in apolipoprotein E deficient mice.
Topics: Angiotensin II; Animals; Aortic Diseases; Apolipoproteins E; Arteriosclerosis; Cardiac Output, High; Cardiomegaly; Cardiovascular System; Enzyme Inhibitors; Estradiol; Hypercholesterolemia; Hyperglycemia; Mice; Mice, Knockout; NG-Nitroarginine Methyl Ester; Phenotype; Simvastatin | 2005 |
[Atherosclerosis imaging to assess plaque progression].
Topics: Adult; Aged; Animals; Aortic Diseases; Arteriosclerosis; Calcinosis; Cardiovascular Diseases; Carotid Artery Diseases; Clinical Trials as Topic; Coronary Angiography; Coronary Artery Disease; Cost-Benefit Analysis; Disease Progression; Female; Follow-Up Studies; Humans; Hypolipidemic Agents; Magnetic Resonance Imaging; Male; Middle Aged; Randomized Controlled Trials as Topic; Risk Factors; Simvastatin; Time Factors; Tomography, X-Ray Computed | 2005 |
Pharmacology of competitive inhibitors of HMG-CoA reductase.
Topics: Animals; Anticholesteremic Agents; Arteriosclerosis; Cattle; Cells, Cultured; Chick Embryo; Cholesterol; Cricetinae; Dogs; Guinea Pigs; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Lipids; Lipoproteins; Lovastatin; Mevalonic Acid; Mice; Organ Specificity; Rabbits; Rats; Simvastatin | 1995 |
[The pharmacology of the statins: the evidence of a direct antiatherosclerotic action].
Topics: Animals; Arteriosclerosis; Cell Division; Cell Movement; Cells, Cultured; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Fatty Acids, Monounsaturated; Fluvastatin; Indoles; Lovastatin; Pravastatin; Rats; Rats, Sprague-Dawley; Simvastatin | 1995 |
Statins do more than just lower cholesterol.
Topics: Anticholesteremic Agents; Arteries; Arteriosclerosis; Blood; Cholesterol; Endothelium, Vascular; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pravastatin; Simvastatin | 1996 |
Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
Topics: Anticholesteremic Agents; Arteriosclerosis; Brain; Enzyme Inhibitors; Fatty Acids, Monounsaturated; Fluvastatin; Food-Drug Interactions; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Liver; Lovastatin; Pravastatin; Simvastatin | 1997 |
[Prevention and therapy of vascular damage and endothelial dysfunction with hypocholesteremic agents].
Topics: Anticholesteremic Agents; Arteriosclerosis; Cholesterol; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Diet; Endothelium, Vascular; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Lovastatin; Male; Mevalonic Acid; Middle Aged; Physical Exertion; Primary Prevention; Simvastatin; Time Factors | 1998 |
Peripheral neuropathy and lipid-lowering therapy.
Topics: Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Middle Aged; Naphthalenes; Niacin; Peripheral Nervous System Diseases; Pravastatin; Pyrroles; Simvastatin | 1998 |
[Statins have other beneficial properties besides their cholesterol lowering effect].
Topics: Anticholesteremic Agents; Arteriosclerosis; Blood Coagulation; Clinical Trials as Topic; Endothelium, Vascular; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunity, Cellular; Lovastatin; Pravastatin; Simvastatin | 1998 |
[Antilipemic agents and atherothrombosis. Effects of antilipemic agents on blood platelet function, coagulation and fibrinolysis].
Topics: Anticholesteremic Agents; Antiporters; Arteriosclerosis; Bezafibrate; Blood Coagulation; Blood Coagulation Factors; Blood Platelets; Clinical Trials as Topic; Clofibric Acid; Fenofibrate; Fibrinolysis; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lovastatin; Niacin; Pravastatin; Risk Factors; Simvastatin; Thrombosis | 1998 |
[Statins (HMG-CoA reductase inhibitors), cholesterol and stroke].
Topics: Adult; Arteriosclerosis; Cerebrovascular Disorders; Cholesterol; Clinical Trials as Topic; Drug Evaluation; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Ischemic Attack, Transient; Lipoproteins, HDL; Lipoproteins, LDL; Lovastatin; Male; Middle Aged; Pravastatin; Risk Factors; Simvastatin; Triglycerides | 1998 |
Strategies for the management of diabetic dyslipidaemia.
Topics: Arteriosclerosis; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Humans; Hyperlipidemias; Hypoglycemic Agents; Hypolipidemic Agents; Male; Metformin; Risk Factors; Simvastatin | 1999 |
Low-density lipoprotein-independent effects of statins.
Topics: Animals; Anticholesteremic Agents; Arteriosclerosis; Blood Coagulation; Cholesterol, LDL; Coronary Disease; Endothelins; Endothelium, Vascular; Humans; Simvastatin; Stroke | 1999 |
[Additional effects of statins independent of the cholesterol-lowering as yet not shown to be clinically relevant].
Topics: Anticholesteremic Agents; Arteriosclerosis; Clinical Trials as Topic; Confounding Factors, Epidemiologic; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Pravastatin; Simvastatin | 2000 |
Non-lipid-related effects of statins.
Topics: Animals; Arteriosclerosis; Blood Coagulation; Cholesterol; Cholesterol, LDL; Endothelium, Vascular; Esterification; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Pravastatin; Simvastatin | 2000 |
[Advance in clinical studies on atherosclerosis].
Topics: Animals; Anticholesteremic Agents; Arteriosclerosis; Cerebrovascular Disorders; Coronary Disease; Humans; Randomized Controlled Trials as Topic; Simvastatin | 2000 |
[The role of HDL in the prevention of cardiovascular events].
Topics: Anticholesteremic Agents; Arteriosclerosis; Aryldialkylphosphatase; Atorvastatin; Cholesterol, HDL; Esterases; Fatty Acids, Monounsaturated; Fluvastatin; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Lipid Peroxidation; Lovastatin; Phosphatidylcholine-Sterol O-Acyltransferase; Pyrroles; Simvastatin | 2001 |
Pharmacology and clinical experience with simvastatin.
Topics: Aged; Arteriosclerosis; Cholesterol, LDL; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Simvastatin; Treatment Outcome | 2001 |
Synthetic statins: more data on newer lipid-lowering agents.
Topics: Arteriosclerosis; Atorvastatin; Clinical Trials as Topic; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Lipids; Pyridines; Pyrroles; Simvastatin | 2001 |
[Substantiation of increasing doses of statins in clinical practice].
Topics: Adult; Aged; Angiography; Animals; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Clinical Trials as Topic; Colestipol; Coronary Disease; Dogs; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Lipids; Lovastatin; Male; Meta-Analysis as Topic; Middle Aged; Primates; Prospective Studies; Pyrroles; Retrospective Studies; Risk Factors; Simvastatin; Time Factors | 2001 |
The use of fibrates and of statins in preventing atherosclerosis in diabetes.
Topics: Anticholesteremic Agents; Arteriosclerosis; Clinical Trials as Topic; Clofibrate; Diabetes Complications; Diabetes Mellitus; Humans; Hypolipidemic Agents; Pravastatin; Simvastatin | 2001 |
Mechanism of action and biological profile of HMG CoA reductase inhibitors. A new therapeutic alternative.
Topics: Anticholesteremic Agents; Arteriosclerosis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Simvastatin | 1988 |
30 trial(s) available for simvastatin and Arteriosclerosis
| Article | Year |
|---|---|
Aortic plaque regression as determined by magnetic resonance imaging with high-dose and low-dose statin therapy.
Topics: Aged; Aortic Diseases; Arteriosclerosis; Cholesterol; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Image Processing, Computer-Assisted; Magnetic Resonance Imaging, Cine; Male; Simvastatin | 2008 |
[Color Doppler ultrasound evaluation of a Chinese herbal formula in treating lower limb arteriosclerosis: a randomized controlled trial].
Topics: Aged; Aged, 80 and over; Arteriosclerosis; Drug Therapy, Combination; Drugs, Chinese Herbal; Female; Humans; Lower Extremity; Male; Phytotherapy; Simvastatin; Ultrasonography, Doppler, Color | 2009 |
Lipid lowering by simvastatin induces regression of human atherosclerotic lesions: two years' follow-up by high-resolution noninvasive magnetic resonance imaging.
Topics: Anticholesteremic Agents; Aorta, Thoracic; Arteriosclerosis; Carotid Arteries; Cholesterol; Cholesterol, LDL; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Lipids; Magnetic Resonance Angiography; Male; Middle Aged; Prospective Studies; Remission Induction; Simvastatin; Time; Treatment Outcome; Vascular Patency | 2002 |
Early statin therapy restores endothelial function in children with familial hypercholesterolemia.
Topics: Adolescent; Arteriosclerosis; Child; Endothelium, Vascular; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipids; Male; Simvastatin; Treatment Outcome | 2002 |
Long term statin treatment reduces lipoprotein(a) concentrations in heterozygous familial hypercholesterolaemia.
Topics: Arteriosclerosis; Atorvastatin; Carotid Arteries; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipoprotein(a); Male; Middle Aged; Pyrroles; Simvastatin | 2003 |
The significance of femoral intima-media thickness and plaque scoring in the Atorvastatin versus Simvastatin on Atherosclerosis Progression (ASAP) study.
Topics: Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Carotid Arteries; Double-Blind Method; Female; Femoral Artery; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Pyrroles; Simvastatin; Tunica Intima; Tunica Media | 2003 |
The relationship between cholesteryl ester transfer protein levels and risk factor profile in patients with familial hypercholesterolemia.
Topics: Administration, Oral; Analysis of Variance; Arteriosclerosis; Atorvastatin; Carrier Proteins; Cholesterol Ester Transfer Proteins; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Glycoproteins; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Linear Models; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Probability; Prognosis; Pyrroles; Reference Values; Risk Assessment; Severity of Illness Index; Simvastatin; Treatment Outcome; Tunica Media | 2004 |
Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study.
Topics: Aged; Arteriosclerosis; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus, Type 2; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Logistic Models; Male; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Triglycerides | 2004 |
Effects of conventional and aggressive statin treatment on markers of endothelial function and inflammation.
Topics: Arteriosclerosis; Atorvastatin; C-Reactive Protein; Chronic Disease; Coronary Artery Disease; E-Selectin; Female; Fibrinogen; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Middle Aged; Nitric Oxide; Pyrroles; Simvastatin; Treatment Outcome | 2004 |
Long-term effects of statins on arterial pressure and stiffness of hypertensives.
Topics: Anticholesteremic Agents; Arteriosclerosis; Blood Pressure; C-Reactive Protein; Cholesterol; Elasticity; Fatty Acids, Monounsaturated; Female; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemias; Hypertension; Indoles; Male; Middle Aged; Pravastatin; Prospective Studies; Pulsatile Flow; Simvastatin; Single-Blind Method | 2005 |
[Study of diagnostic criteria of intima-media thickening and effects of drugs on peripheral arteries].
Topics: Adult; Aged; Anticholesteremic Agents; Aorta, Thoracic; Arteriosclerosis; Captopril; Carotid Arteries; Carotid Stenosis; Female; Femoral Artery; Humans; Male; Middle Aged; Reference Standards; Simvastatin; Tunica Intima; Tunica Media; Ultrasonography | 2004 |
Statin-induced cholesterol lowering and plaque regression after 6 months of magnetic resonance imaging-monitored therapy.
Topics: Aged; Aorta, Thoracic; Aortic Diseases; Arteriosclerosis; Cholesterol, LDL; Comorbidity; Coronary Disease; Diabetes Mellitus; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Magnetic Resonance Imaging; Male; Middle Aged; Observer Variation; Prospective Studies; Reproducibility of Results; Simvastatin; Smoking; Stroke | 2004 |
Elevated soluble tumor necrosis factor receptor levels in non-obese adults with the atherogenic dyslipoproteinemia.
Topics: Arteriosclerosis; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemias; Male; Middle Aged; Pravastatin; Receptors, Tumor Necrosis Factor; Receptors, Tumor Necrosis Factor, Type I; Receptors, Tumor Necrosis Factor, Type II; Simvastatin; Tumor Necrosis Factor Decoy Receptors | 2004 |
Tracking regression and progression of atherosclerosis in human carotid arteries using high-resolution magnetic resonance imaging.
Topics: Aged; Aged, 80 and over; Algorithms; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Carotid Arteries; Carotid Artery Diseases; Disease Progression; Female; Follow-Up Studies; Heptanoic Acids; Humans; Image Enhancement; Magnetic Resonance Imaging; Male; Middle Aged; Observer Variation; Pilot Projects; Pravastatin; Pyrroles; Reproducibility of Results; Simvastatin | 2004 |
Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome.
Topics: Adult; Aged; Aged, 80 and over; Arteriosclerosis; Atorvastatin; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Metabolic Syndrome; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2005 |
Effects of aggressive versus conventional lipid-lowering therapy by simvastatin on human atherosclerotic lesions: a prospective, randomized, double-blind trial with high-resolution magnetic resonance imaging.
Topics: Adult; Aged; Aged, 80 and over; Aorta, Thoracic; Arteriosclerosis; Carotid Arteries; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Hypolipidemic Agents; Magnetic Resonance Imaging; Male; Middle Aged; Prospective Studies; Simvastatin; Time Factors | 2005 |
Prevention and treatment of graft vessel disease after heart transplantation.
Topics: Adult; Arteriosclerosis; Blood Component Removal; Cholesterol; Double-Blind Method; Female; Graft Occlusion, Vascular; Graft vs Host Disease; Heart Transplantation; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Oligopeptides; Peptides, Cyclic; Prospective Studies; Risk Factors; Simvastatin; Somatostatin; Tissue Donors | 1995 |
Effects of HMG-CoA reductase inhibition on erythrocyte membrane cholesterol and acyl chain composition.
Topics: Anticholesteremic Agents; Arteriosclerosis; Cholesterol; Erythrocyte Membrane; Fatty Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Membrane Lipids; Osmotic Fragility; Simvastatin | 1996 |
Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)
Topics: Anticholesteremic Agents; Arteriosclerosis; Blood Pressure; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetic Angiopathies; Double-Blind Method; Female; Humans; Lovastatin; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Placebos; Prognosis; Risk Factors; Scandinavian and Nordic Countries; Simvastatin; Survival Rate; Time Factors; Triglycerides | 1997 |
Prevention of cardiovascular disease: the Scandinavian experience.
Topics: Adult; Aged; Anticholesteremic Agents; Arteriosclerosis; Cardiovascular Diseases; Cholesterol, LDL; Coronary Disease; Humans; Hypercholesterolemia; Middle Aged; Scandinavian and Nordic Countries; Simvastatin | 1998 |
Treating patients with documented atherosclerosis to National Cholesterol Education Program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin.
Topics: Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Cholesterol, LDL; Colestipol; Combined Modality Therapy; Diet, Fat-Restricted; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Indoles; Lovastatin; Male; Pyrroles; Simvastatin; Treatment Outcome | 1998 |
[Serum leptin, early atherosclerosis and hypolipidemia (a new, previously undescribed effect of pravastatin, a hypolipemic agent)].
Topics: Adipose Tissue; Age of Onset; Arteriosclerosis; Body Mass Index; Female; Fenofibrate; Humans; Hypolipidemic Agents; Insulin; Leptin; Male; Middle Aged; Pravastatin; Proteins; Simvastatin | 1998 |
The effect of cholesterol lowering on carotid and femoral artery wall stiffness and thickness in patients with familial hypercholesterolaemia.
Topics: Adult; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Blood Pressure; Carotid Arteries; Cholesterol, HDL; Cholesterol, LDL; Elasticity; Family Health; Female; Femoral Artery; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Simvastatin; Triglycerides; Tunica Intima | 2000 |
[Unaltered homocysteine levels during simvastatin therapy].
Topics: Adult; Anticholesteremic Agents; Arteriosclerosis; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Female; Homocysteine; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Risk Factors; Severity of Illness Index; Sex Factors; Simvastatin; Smoking; Time Factors; Treatment Outcome; Triglycerides | 2000 |
Effects of simvastatin treatment on sICAM-1 and sE-selectin levels in hypercholesterolemic subjects.
Topics: Adult; Aged; Anticholesteremic Agents; Arteriosclerosis; Cholesterol; E-Selectin; Endothelium, Vascular; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Intercellular Adhesion Molecule-1; Male; Middle Aged; Simvastatin | 2001 |
Non-lipid effects of statin on hypercholesterolemic patients established to have coronary artery disease who remained hypercholesterolemic while eating a step-II diet.
Topics: Aged; Anticholesteremic Agents; Arteriosclerosis; Biomarkers; Chemokine CCL2; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Data Interpretation, Statistical; Endothelium, Vascular; Humans; Hypercholesterolemia; Matrix Metalloproteinase 9; Middle Aged; Simvastatin; Triglycerides; Tumor Necrosis Factor-alpha | 2001 |
Effects of lipid-lowering by simvastatin on human atherosclerotic lesions: a longitudinal study by high-resolution, noninvasive magnetic resonance imaging.
Topics: Aorta; Aortic Diseases; Arteriosclerosis; Carotid Arteries; Carotid Stenosis; Cholesterol; Cholesterol, LDL; Humans; Hypolipidemic Agents; Longitudinal Studies; Magnetic Resonance Imaging; Remission Induction; Simvastatin; Treatment Outcome; Vascular Patency | 2001 |
[Results of clinical epidemiology and intervention trial of hyperlipidemia in Japan].
Topics: Adult; Aged; Anticholesteremic Agents; Arteriosclerosis; Female; Humans; Hypercholesterolemia; Hyperlipidemias; Japan; Male; Middle Aged; Pravastatin; Prospective Studies; Simvastatin; Treatment Outcome | 2002 |
Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia.
Topics: Adolescent; Adult; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Azetidines; Blood Component Removal; Child; Cholesterol, LDL; Creatine Kinase; Diet Therapy; Dose-Response Relationship, Drug; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Homozygote; Humans; Hyperlipoproteinemia Type II; Liver Function Tests; Male; Pyrroles; Simvastatin; Treatment Outcome | 2002 |
The use of simvastatin, an HMG CoA reductase inhibitor, in older patients with hypercholesterolemia and atherosclerosis.
Topics: Aged; Anticholesteremic Agents; Arteriosclerosis; Cataract; Cholesterol, HDL; Cholesterol, LDL; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Lovastatin; Male; Randomized Controlled Trials as Topic; Simvastatin | 1990 |
58 other study(ies) available for simvastatin and Arteriosclerosis
| Article | Year |
|---|---|
Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.
Topics: Animals; Arteriosclerosis; Cholesterol, LDL; Clinical Trials as Topic; Drug Evaluation, Preclinical; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Molecular Structure; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2001 |
LDL Cholesterol Reduction Variability with Different Types and Doses of Statins in Monotherapy or Combined with Ezetimibe. Results from the Spanish Arteriosclerosis Society Dyslipidaemia Registry.
Topics: Anticholesteremic Agents; Arteriosclerosis; Cholesterol, LDL; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Registries; Rosuvastatin Calcium; Simvastatin | 2022 |
Simvastatin Attenuates Oxidative Stress, NF-κB Activation, and Artery Calcification in LDLR-/- Mice Fed with High Fat Diet via Down-regulation of Tumor Necrosis Factor-α and TNF Receptor 1.
Topics: Animals; Arteriosclerosis; Calcinosis; Diet, High-Fat; Down-Regulation; Gene Knockout Techniques; Humans; Male; Mice; Mice, Knockout; NF-kappa B; Oxidative Stress; Receptors, LDL; Receptors, Tumor Necrosis Factor, Type I; Simvastatin; Tumor Necrosis Factor-alpha | 2015 |
[Effects of simvastatin on vasa vasorum and aortic endothelial function in rats].
Topics: Animals; Aorta; Arteriosclerosis; Endothelium, Vascular; Hyperlipidemias; Hypolipidemic Agents; Male; Nitric Oxide; Random Allocation; Rats; Rats, Sprague-Dawley; Simvastatin; Vasa Vasorum; Vascular Endothelial Growth Factor A | 2010 |
Progenitor cell mobilizing treatments prevent experimental transplant arteriosclerosis.
Topics: Animals; Anti-HIV Agents; Anticholesteremic Agents; Anticoagulants; Aorta; Arteriosclerosis; Benzylamines; Cyclams; Endothelium, Vascular; Graft Rejection; Green Fluorescent Proteins; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Heterocyclic Compounds; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Transgenic; Molecular Weight; Polysaccharides; Simvastatin; Transplantation, Homologous; Tunica Intima | 2012 |
Statins reduce inflammation in atheroma of nonhuman primates independent of effects on serum cholesterol.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arteriosclerosis; Cholesterol; Cholesterol, Dietary; Drug Administration Schedule; Endothelium, Vascular; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Lipoproteins; Macaca fascicularis; Male; Matrix Metalloproteinases; Pravastatin; Simvastatin; Thromboplastin; Tunica Intima; Tunica Media; Vascular Cell Adhesion Molecule-1; Vasodilation | 2002 |
[Dangerous plaque often symptom-free. ACE inhibitors prevent rupture].
Topics: Angiotensin-Converting Enzyme Inhibitors; Arteriosclerosis; Cerebral Infarction; Clinical Trials as Topic; Humans; Myocardial Infarction; Ramipril; Risk Factors; Simvastatin | 2002 |
Simvastatin promotes atherosclerotic plaque stability in apoE-deficient mice independently of lipid lowering.
Topics: Animals; Apolipoproteins E; Arteriosclerosis; Cholesterol; Disease Progression; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Mice; Mice, Inbred C57BL; Regression Analysis; Simvastatin; Time Factors | 2002 |
Simvastatin reduces NF-kappaB activity in peripheral mononuclear and in plaque cells of rabbit atheroma more markedly than lipid lowering diet.
Topics: Animals; Arteriosclerosis; Diet, Atherogenic; Femoral Artery; Hypolipidemic Agents; Interleukin-8; Leukocytes, Mononuclear; Macrophage Activation; Male; Matrix Metalloproteinase 3; Models, Animal; NF-kappa B; Rabbits; Random Allocation; Simvastatin | 2003 |
Comparison of the effects of atorvastatin versus simvastatin on subclinical atherosclerosis in primary preventionas determined by electronbeam tomography.
Topics: Analysis of Variance; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Chi-Square Distribution; Disease Progression; Female; Heptanoic Acids; Humans; Lipids; Male; Middle Aged; Niacin; Primary Prevention; Pyrroles; Risk Factors; Simvastatin; Tomography, X-Ray Computed; Treatment Outcome | 2003 |
Simvastatin inhibits expression of tissue factor in advanced atherosclerotic lesions of apolipoprotein E deficient mice independently of lipid lowering: potential role of simvastatin-mediated inhibition of Egr-1 expression and activation.
Topics: Animals; Apolipoproteins E; Arteriosclerosis; Base Sequence; Chemokine CCL2; Cholesterol; Culture Techniques; Disease Models, Animal; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Male; Mice; Mice, Inbred Strains; Molecular Sequence Data; Probability; Reverse Transcriptase Polymerase Chain Reaction; Sensitivity and Specificity; Severity of Illness Index; Simvastatin; Thromboplastin | 2003 |
Statins (HMG-CoA reductase inhibitors) reduce CD40 expression in human vascular cells.
Topics: Animals; Arteriosclerosis; Atorvastatin; Blotting, Western; CD40 Antigens; Cells, Cultured; Depression, Chemical; Dose-Response Relationship, Drug; Endothelial Cells; Fibroblasts; Flow Cytometry; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Interferon-gamma; Lovastatin; Macrophages; Mevalonic Acid; Mice; Muscle, Smooth, Vascular; Nitric Oxide Synthase; Pravastatin; Pyrroles; Receptors, Cytoplasmic and Nuclear; Recombinant Proteins; Simvastatin; Transcription Factors | 2003 |
[Studies on the simvastatin effect on the artery of atherosclerotic rabbit using proteomics approaches].
Topics: Animals; Arteries; Arteriosclerosis; Diet, Atherogenic; Fatty Liver; Hypolipidemic Agents; Male; Proteins; Rabbits; Random Allocation; Simvastatin | 2003 |
HMG-CoA reductase inhibitors suppress maturation of human dendritic cells: new implications for atherosclerosis.
Topics: Adjuvants, Immunologic; Antigens, CD; Arteriosclerosis; Atorvastatin; B7-2 Antigen; Bone Marrow Cells; CD83 Antigen; Cell Survival; Cells, Cultured; Dendritic Cells; Flow Cytometry; Heptanoic Acids; HLA-DR Antigens; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoglobulins; Lymphocyte Culture Test, Mixed; Membrane Glycoproteins; Pyrroles; Receptors, CCR7; Receptors, Chemokine; Simvastatin; Time Factors; Tumor Necrosis Factor Receptor Superfamily, Member 7 | 2004 |
The selective peroxisomal proliferator-activated receptor-gamma agonist has an additive effect on plaque regression in combination with simvastatin in experimental atherosclerosis: in vivo study by high-resolution magnetic resonance imaging.
Topics: Animals; Anti-Inflammatory Agents; Arteriosclerosis; Drug Synergism; Hypolipidemic Agents; Magnetic Resonance Imaging; Male; Models, Animal; Rabbits; Receptors, Cytoplasmic and Nuclear; Remission Induction; Simvastatin; Transcription Factors | 2004 |
[Effects of angiotensin II receptor blockers, angiotensin converting enzyme inhibitors, 3-hydroxy-3-methyl glutaryl (HMG) CoA reductase inhibitors, amlodipine and epalrestat on cultured basilar artery smooth muscle cell proliferation].
Topics: Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Arteriosclerosis; Basilar Artery; Calcium Channel Blockers; Cell Division; Cells, Cultured; Depression, Chemical; Fatty Acids, Monounsaturated; Fluvastatin; Guinea Pigs; Hydroxymethylglutaryl CoA Reductases; Indoles; Muscle, Smooth, Vascular; Oxidative Stress; Reactive Oxygen Species; Rhodanine; Simvastatin; Thiazolidines | 2004 |
Comparison of levels of matrix metalloproteinases, tissue inhibitor of metalloproteinases, interleukins, and tissue necrosis factor in carotid endarterectomy specimens from patients on versus not on statins preoperatively.
Topics: Aged; Aged, 80 and over; Arteriosclerosis; Atorvastatin; Carotid Artery Diseases; Endarterectomy, Carotid; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Interleukins; Male; Matrix Metalloproteinases; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Tissue Inhibitor of Metalloproteinases; Tumor Necrosis Factor-alpha; Ultrasonography | 2004 |
Increased soluble CD40L levels are reduced by long-term simvastatin treatment in peritoneally dialyzed patients.
Topics: Arteriosclerosis; C-Reactive Protein; CD40 Ligand; E-Selectin; Endothelium, Vascular; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Inflammation; Kidney Failure, Chronic; Male; Middle Aged; P-Selectin; Peritoneal Dialysis, Continuous Ambulatory; Platelet Aggregation; Simvastatin; Solubility; von Willebrand Factor | 2004 |
Atheroma stabilizing effects of simvastatin due to depression of macrophages or lipid accumulation in the atheromatous plaques of coronary plaque-prone WHHL rabbits.
Topics: Animals; Aorta; Arteriosclerosis; Disease Models, Animal; Hypolipidemic Agents; In Situ Nick-End Labeling; Lipids; Macrophages; Male; Muscle, Smooth, Vascular; Rabbits; Simvastatin | 2005 |
The changes in the endothelial expression of cell adhesion molecules and iNOS in the vessel wall after the short-term administration of simvastatin in rabbit model of atherosclerosis.
Topics: Animals; Aorta, Thoracic; Arteriosclerosis; Carotid Arteries; Cell Adhesion Molecules; Cholesterol; Diet, Atherogenic; Disease Models, Animal; Drug Administration Schedule; Endothelial Cells; Immunohistochemistry; Male; Muscle, Smooth, Vascular; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Rabbits; Simvastatin; Time Factors | 2005 |
A comparative study of efficacy of tibolone and simvastatin on atherosclerosis in ovariectomized cholesterol-fed rabbits.
Topics: Animals; Anticholesteremic Agents; Arteriosclerosis; Cholesterol; Diet, Atherogenic; Disease Models, Animal; DNA Primers; Estrogen Receptor Modulators; Female; Hypercholesterolemia; Norpregnenes; Ovariectomy; Polymerase Chain Reaction; Rabbits; Receptors, Estrogen; Receptors, LDL; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Simvastatin | 2005 |
[Effects of atorvastatin, fluvastatin, pravastatin, and simvastatin on endothelial function, lipid peroxidation, and aortic atherosclerosis in hypercholesterolemic rabbits].
Topics: Animals; Anticholesteremic Agents; Aortic Diseases; Arteriosclerosis; Atorvastatin; Cholesterol; Cholesterol, LDL; Endothelium, Vascular; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Hypercholesterolemia; Indoles; Lipid Peroxidation; Male; Malondialdehyde; Pravastatin; Pyrroles; Rabbits; Simvastatin | 2005 |
[High doses statins administration causing rhabdomyolysis: case report].
Topics: Acute Kidney Injury; Aged; Arteriosclerosis; Drug Interactions; Fatal Outcome; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Rhabdomyolysis; Simvastatin | 2005 |
Measuring effects of antiatherosclerotic therapies.
Topics: Arteriosclerosis; Carotid Arteries; Endpoint Determination; Humans; Hypolipidemic Agents; Magnetic Resonance Imaging; Reproducibility of Results; Sensitivity and Specificity; Simvastatin | 2006 |
Clinical characteristics and outcomes of Chinese patients with cholesterol crystal embolism after coronary intervention.
Topics: Acute Kidney Injury; Aged; Angioplasty, Balloon, Coronary; Arteriosclerosis; Atorvastatin; China; Coronary Angiography; Embolism, Cholesterol; Female; Heptanoic Acids; Humans; Hypolipidemic Agents; Male; Prognosis; Prospective Studies; Pyrroles; Risk Assessment; Risk Factors; Simvastatin; Treatment Outcome | 2006 |
Pathogenesis of atherosclerosis and the role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
Topics: Animals; Anticholesteremic Agents; Arteriosclerosis; Cell Division; Cell Movement; Cells, Cultured; Cholesterol Esters; Diterpenes; Farnesol; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Macrophages, Peritoneal; Male; Mevalonic Acid; Mice; Mice, Inbred BALB C; Muscle, Smooth, Vascular; Pravastatin; Rabbits; Rats; Rats, Sprague-Dawley; Simvastatin | 1995 |
Development and progression of atherosclerosis in aorta from heterozygous and homozygous WHHL rabbits. Effects of simvastatin treatment.
Topics: Age Factors; Animals; Aorta; Aorta, Thoracic; Arteriosclerosis; Carbachol; Cholesterol; Endothelium, Vascular; Heterozygote; Homozygote; Hyperlipoproteinemia Type II; Lovastatin; Phenylephrine; Rabbits; Simvastatin; Vasoconstriction; Vasodilation | 1995 |
Long-term effects of simvastatin in hypercholesterolemic patients with NIDDM and additional atherosclerotic risk factors. Hyogo Simvastatin Study Group.
Topics: Anticholesteremic Agents; Arteriosclerosis; Diabetes Mellitus, Type 2; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Prospective Studies; Risk Factors; Simvastatin | 1995 |
Simvastatin decreases accelerated graft vessel disease after heart transplantation in an animal model.
Topics: Animals; Arteriosclerosis; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Creatinine; Graft Survival; Heart Transplantation; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Rats; Rats, Inbred BN; Rats, Inbred Lew; Simvastatin; Tacrolimus; Transplantation, Homologous; Transplantation, Isogeneic | 1993 |
Beneficial effects of simvastatin may be due to non-lipid actions.
Topics: Anticholesteremic Agents; Arteriosclerosis; Coronary Disease; Humans; Lovastatin; Simvastatin | 1995 |
Primary prevention of stroke.
Topics: Acyl Coenzyme A; Anticholesteremic Agents; Arteriosclerosis; Cerebrovascular Disorders; Controlled Clinical Trials as Topic; Enzyme Inhibitors; Humans; Hypercholesterolemia; Lovastatin; Meta-Analysis as Topic; Oxidoreductases; Pravastatin; Simvastatin | 1996 |
Levels of soluble cell adhesion molecules in patients with dyslipidemia.
Topics: Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Cell Adhesion Molecules; Colestipol; Drug Therapy, Combination; E-Selectin; Endothelium, Vascular; Enzyme Inhibitors; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertriglyceridemia; Hypolipidemic Agents; Intercellular Adhesion Molecule-1; Lovastatin; Male; Middle Aged; Pyrroles; Risk Factors; Simvastatin; Solubility; Vascular Cell Adhesion Molecule-1 | 1996 |
Improved survival with statin therapy.
Topics: Anticholesteremic Agents; Arteriosclerosis; Cholesterol, LDL; Coronary Disease; Humans; Lovastatin; Pravastatin; Simvastatin | 1996 |
HMG-CoA reductase inhibitors suppress macrophage growth induced by oxidized low density lipoprotein.
Topics: Animals; Arteriosclerosis; Cell Division; Cholesterol; Drug Interactions; Enzyme Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Lovastatin; Macrophages; Male; Mevalonic Acid; Mice; Mice, Inbred C3H; Oxidation-Reduction; Pravastatin; Simvastatin | 1997 |
Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S).
Topics: Adult; Aged; Arteriosclerosis; Disease Progression; Female; Humans; Hypolipidemic Agents; Ischemia; Male; Middle Aged; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome | 1998 |
Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors.
Topics: Animals; Aorta; Arteriosclerosis; Cattle; Cells, Cultured; Endothelium, Vascular; Enzyme Activation; Enzyme Inhibitors; Gene Expression Regulation, Enzymologic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Lovastatin; Mevalonic Acid; Nitric Oxide Synthase; RNA, Messenger; Saphenous Vein; Simvastatin; Transcription, Genetic | 1998 |
IDL composition and angiographically determined progression of atherosclerotic lesions during simvastatin therapy.
Topics: Adult; Aged; Anticholesteremic Agents; Arteriosclerosis; Cholesterol; Cholesterol Esters; Coronary Angiography; Female; Humans; Lipoproteins; Lipoproteins, IDL; Male; Middle Aged; Simvastatin; Triglycerides | 1998 |
[Therapeutic management of hypercholesterolemia].
Topics: Anticholesteremic Agents; Arteriosclerosis; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Forecasting; Humans; Hypercholesterolemia; Prospective Studies; Risk Factors; Scandinavian and Nordic Countries; Scotland; Simvastatin | 1998 |
Efficacy and safety of simvastatin 80 mg/day in hypercholesterolemic patients: why is someone still using the phase I diet for patients at risk for atherosclerosis?
Topics: American Heart Association; Anticholesteremic Agents; Arteriosclerosis; Clinical Trials, Phase I as Topic; Clinical Trials, Phase III as Topic; Diet, Vegetarian; Dietary Fats; Disease Progression; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Risk Factors; Simvastatin; United States | 1999 |
Differential cholesteryl ester accumulation in two human vascular smooth muscle cell subpopulations exposed to aggregated LDL: effect of PDGF-stimulation and HMG-CoA reductase inhibition.
Topics: Arteriosclerosis; Becaplermin; Cell Division; Cells, Cultured; Cholesterol; Cholesterol Esters; DNA Replication; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Muscle, Smooth, Vascular; Platelet-Derived Growth Factor; Proto-Oncogene Proteins c-sis; Pulmonary Artery; Recombinant Proteins; Simvastatin | 1999 |
Nitric oxide synthase II (NOS II) gene expression correlates with atherosclerotic intimal thickening. Preventive effects of HMG-CoA reductase inhibitors.
Topics: Animals; Arteriosclerosis; Atorvastatin; Chemokine CCL2; Cholesterol; Cholesterol, Dietary; Disease Models, Animal; DNA; Down-Regulation; Fibrinogen; Gene Expression; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Macrophages; Muscle, Smooth, Vascular; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Polymerase Chain Reaction; Pyrroles; Rabbits; Simvastatin; Tunica Intima | 1999 |
Efficacy of vitamin E compared with either simvastatin or atorvastatin in preventing the progression of atherosclerosis in homozygous familial hypercholesterolemia.
Topics: Adolescent; Adult; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Carotid Arteries; Child; Child, Preschool; Cholesterol, HDL; Cholesterol, LDL; Disease Progression; DNA; Female; Heptanoic Acids; Homozygote; Humans; Hyperlipoproteinemia Type II; Male; Mutation; Pyrroles; Receptors, LDL; Simvastatin; Treatment Outcome; Triglycerides; Tunica Intima; Vitamin E | 1999 |
Oxidized lipoproteins and endothelium.
Topics: Animals; Apoptosis; Arteriosclerosis; Cells, Cultured; Endothelium, Vascular; HSP70 Heat-Shock Proteins; Humans; Hypercholesterolemia; In Vitro Techniques; Lipoproteins, LDL; Male; Oxidation-Reduction; Rabbits; Simvastatin | 2000 |
Pleiotropic effects of statins in atherosclerosis and diabetes.
Topics: Animals; Arteriosclerosis; Atorvastatin; Cell Division; Cell Movement; Cells, Cultured; Cholesterol; Cholesterol Esters; Diabetes Complications; Diabetes Mellitus; Diabetic Angiopathies; Endocytosis; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lipoproteins; Lovastatin; Macrophages; Macrophages, Peritoneal; Mice; Mice, Inbred BALB C; Muscle, Smooth; Pyridines; Pyrroles; Simvastatin | 2000 |
Molecular multitasking: statins lead to more arteries, less plaque.
Topics: Anticholesteremic Agents; Arteriosclerosis; Enzyme Activation; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Neovascularization, Physiologic; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Protein Kinases; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Signal Transduction; Simvastatin | 2000 |
Simvastatin, capillary permeability, and acetylcholine-mediated vasomotion in atherosclerotic, hypercholesterolemic men.
Topics: Acetylcholine; Aged; Anticholesteremic Agents; Arteriosclerosis; Blood Pressure; Capillary Permeability; Case-Control Studies; Cholesterol, LDL; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Nitroprusside; Simvastatin; Time Factors; Vasoconstriction; Vasodilation; Vasodilator Agents | 2000 |
Lipid treatment goals achieved in patients treated with statin drugs in Norwegian general practice.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Cross-Sectional Studies; Family Practice; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lipids; Male; Middle Aged; Norway; Pravastatin; Pyridines; Pyrroles; Retrospective Studies; Simvastatin; Surveys and Questionnaires | 2000 |
Simvastatin improves disturbed endothelial barrier function.
Topics: Animals; Aorta; Arteriosclerosis; Capillary Permeability; Cell Membrane Permeability; Cells, Cultured; Cholesterol; Cholesterol, LDL; Disease Models, Animal; Endothelium, Vascular; Humans; Hypercholesterolemia; Rabbits; Simvastatin | 2000 |
Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents; Anticholesteremic Agents; Aorta; Apolipoproteins E; Arteriosclerosis; Carrageenan; Cholesterol; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hindlimb; Injections, Subcutaneous; Lipids; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Simvastatin | 2001 |
3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition prevents endothelial NO synthase downregulation by atherogenic levels of native LDLs: balance between transcriptional and posttranscriptional regulation.
Topics: Arteriosclerosis; Cells, Cultured; Down-Regulation; Endothelium, Vascular; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Mevalonic Acid; Nitric Oxide Synthase; Promoter Regions, Genetic; RNA Stability; RNA, Messenger; Simvastatin; Transcription, Genetic | 2001 |
HMG-CoA reductase inhibitor stabilizes rabbit atheroma by increasing basal NO and decreasing superoxide.
Topics: Animals; Aorta; Aorta, Thoracic; Arteriosclerosis; Cholesterol; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Male; Nitrates; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Nitrites; Rabbits; RNA, Messenger; Simvastatin; Superoxides; Vasoconstriction | 2001 |
The combined effect of inhibiting both ACAT and HMG-CoA reductase may directly induce atherosclerotic lesion regression.
Topics: Acetamides; Acetates; Animals; Arteriosclerosis; Coenzyme A-Transferases; Drug Therapy, Combination; Hydroxymethylglutaryl CoA Reductases; Hypolipidemic Agents; Rabbits; Simvastatin; Sulfonamides; Sulfonic Acids | 2001 |
Ezetimibe (Schering-Plough).
Topics: Animals; Anticholesteremic Agents; Arteriosclerosis; Azetidines; Bile; Cholesterol; Cholesterol, LDL; Clinical Trials, Phase II as Topic; Down-Regulation; Drug Combinations; Drug Evaluation, Preclinical; Drug Therapy, Combination; Drugs, Investigational; Ezetimibe; Forecasting; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Intestinal Absorption; Intestinal Mucosa; Intestines; Molecular Structure; Simvastatin | 2001 |
Establishment of a secondary prevention program for coronary bypass patients.
Topics: Anticholesteremic Agents; Arteriosclerosis; Coronary Artery Bypass; Humans; North Carolina; Perioperative Care; Preventive Health Services; Simvastatin | 2001 |
Homocysteine induces 3-hydroxy-3-methylglutaryl coenzyme a reductase in vascular endothelial cells: a mechanism for development of atherosclerosis?
Topics: Arteriosclerosis; Caveolin 1; Caveolins; Cells, Cultured; Cholesterol; Culture Media, Conditioned; Dose-Response Relationship, Drug; Endothelium, Vascular; Enzyme Induction; Free Radical Scavengers; Gene Expression; Homocysteine; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Metalloporphyrins; Nitric Oxide; Oligonucleotide Array Sequence Analysis; Risk Factors; RNA Stability; RNA, Messenger; Simvastatin; Up-Regulation | 2002 |
Anti-atherosclerotic effect of simvastatin depends on the presence of apolipoprotein E.
Topics: Acetylcholine; Animals; Aorta; Apolipoproteins E; Arteriosclerosis; Cholesterol, HDL; Cholesterol, LDL; Disease Models, Animal; Endothelium, Vascular; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Mice; Mice, Knockout; Models, Cardiovascular; Muscle Relaxation; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Receptors, LDL; RNA, Messenger; Simvastatin; Treatment Outcome; Triglycerides; Vasodilator Agents | 2002 |
[Simvastatin (MK-733), a new HMG-CoA reductase inhibitor, in the treatment of hypercholesterolemia in elderly patients with atherosclerosis].
Topics: Aged; Alanine Transaminase; Arteriosclerosis; Cholesterol; Cholesterol, LDL; Creatine Kinase; Female; Humans; Hydroxymethylglutaryl CoA Reductases; Hypercholesterolemia; Lipids; Lovastatin; Male; Simvastatin | 1990 |
Preventive effect of MK-733 (simvastatin), an inhibitor of HMG-CoA reductase, on hypercholesterolemia and atherosclerosis induced by cholesterol feeding in rabbits.
Topics: Animals; Aorta; Arteriosclerosis; Cholesterol; Cholesterol, Dietary; Hypercholesterolemia; Lipids; Liver; Lovastatin; Male; Myocardium; Rabbits; Simvastatin | 1989 |